312 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
(such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation … relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA), other litigation and other
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without … limitation the patent litigation and other related proceedings relating to EYLEA), other litigation and other proceedings and government investigations
8-K
EX-99.1
z0i3resr0zuf34ad
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
xt7bqxew5xbqx9wit
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T/A
j6nga8e g2d9
12 Sep 23
Third party tender offer statement (amended)
4:38pm
SC TO-T/A
ifyt xlf2
8 Sep 23
Third party tender offer statement (amended)
4:05pm
SC TO-T
EX-99
61s3q9
25 Aug 23
Third party tender offer statement
7:46am
SC TO-C
EX-99.1
gix12bdv9z2fuc wrh6
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
78wrs
9 Aug 23
Information about tender offer
4:15pm
SC TO-C
EX-99.2
z8cwqkig79rj92kj1
9 Aug 23
Information about tender offer
4:15pm
8-K
EX-99.1
ag8qvr 2tlnc
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
PX14A6G
c62129 bh
18 May 23
Letter to shareholders
4:46pm
8-K
EX-99.1
vcqf 244ffzy6
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am